Literature DB >> 2056943

Factors related to the presentation of patients with thick primary melanomas.

P Hersey1, R W Sillar, C G Howe, R C Burton, S V Darbar, H M Foster, S M Collins, D E Bradley, D Owens.   

Abstract

OBJECTIVE: To identify any characteristics of patients that are associated with presentation with thick primary melanoma.
DESIGN: This was a retrospective survey of the clinical records of 1300 patients attending the Newcastle Melanoma Unit. Characteristics of 131 patients with thick melanomas (defined as 3 mm or greater in thickness) were compared with those of 543 patients with thin melanomas (defined as 0.75 mm or less in thickness). Comparisons were made using contingency table analysis, Wilcoxon rank sum tests, log rank analysis and logistic regression.
SETTING: The Newcastle Melanoma Unit is a tertiary referral centre for the treatment of primary melanoma. PATIENTS: We surveyed all 1300 patients attending the Newcastle Melanoma Unit over the years 1981-1990. They represented approximately 90% of the patients in the Hunter region of New South Wales who developed melanoma during this period. Excluded from analysis were 39 patients with occult primary melanomas, 79 with multiple primary melanomas, 51 with primary melanomas of unknown thickness and seven with incomplete records, leaving 1124 patients in the study. MAIN OUTCOME MEASURES: These were selected before the results were known. The hypothesis was generated following analysis of the data.
RESULTS: Patients with thick primary melanoma were more likely to be men (68% men and 32% women in the thick melanoma group, compared with 45% and 55% respectively in the thin melanoma group, P less than 0.005) over 60 (75% were over 50 years of age in the thick group versus 33% in the thin melanoma group, P less than 0.001) with nodular melanoma (62%, versus 2% in the thin melanoma group, P less than 0.001) and with melanoma on the head and neck (27%, versus 12% in patients with thin melanoma, P less than 0.005). The time from detection of a change in skin to diagnosis was not longer for those with thick compared to those with thin melanomas.
CONCLUSION: The greatest problem of those with thin melanomas.
CONCLUSION: The greatest problem of detecting melanoma at an early (surgically curable) stage appears to be in patients over the age of 50 who have nodular melanoma, particularly in the head and neck.

Entities:  

Mesh:

Year:  1991        PMID: 2056943     DOI: 10.5694/j.1326-5377.1991.tb121217.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  6 in total

Review 1.  A new understanding in the epidemiology of melanoma.

Authors:  Esther Erdei; Salina M Torres
Journal:  Expert Rev Anticancer Ther       Date:  2010-11       Impact factor: 4.512

2.  Marital status and stage at diagnosis of cutaneous melanoma: results from the Surveillance Epidemiology and End Results (SEER) program, 1973-2006.

Authors:  John M McLaughlin; James L Fisher; Electra D Paskett
Journal:  Cancer       Date:  2010-11-10       Impact factor: 6.860

3.  Breslow thickness in the Netherlands: a population-based study of 40 880 patients comparing young and elderly patients.

Authors:  S Kruijff; E Bastiaannet; A B Francken; M Schaapveld; M van der Aa; H J Hoekstra
Journal:  Br J Cancer       Date:  2012-06-19       Impact factor: 7.640

4.  Salvage surgery for a giant melanoma on the back.

Authors:  Schelto Kruijff; Robert Vink; Joost Klaase
Journal:  Rare Tumors       Date:  2011-07-11

5.  Comparison between lentigo maligna melanoma and other histogenetic types of malignant melanoma of the head and neck. Scottish Melanoma Group.

Authors:  N H Cox; T C Aitchison; J M Sirel; R M MacKie
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

6.  Study of the Female Sex Survival Advantage in Melanoma-A Focus on X-Linked Epigenetic Regulators and Immune Responses in Two Cohorts.

Authors:  Abdullah Al Emran; Jérémie Nsengimana; Gaya Punnia-Moorthy; Ulf Schmitz; Stuart J Gallagher; Julia Newton-Bishop; Jessamy C Tiffen; Peter Hersey
Journal:  Cancers (Basel)       Date:  2020-07-28       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.